These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28703529)

  • 1. [Hope for chronic inflammatory diseases : the anti-IL-6 receptor monoclonal antibody tocilizumab].
    Spertini F
    Rev Med Suisse; 2017 Jan; 13(544-545):20-22. PubMed ID: 28703529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases.
    Tanaka T; Narazaki M; Kishimoto T
    FEBS Lett; 2011 Dec; 585(23):3699-709. PubMed ID: 21419125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.
    Lane T; Gillmore JD; Wechalekar AD; Hawkins PN; Lachmann HJ
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S46-53. PubMed ID: 26120866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel therapeutic approach in pulmonary arterial hypertension as a complication of adult-onset Still's disease: targeting IL-6.
    Kadavath S; Zapantis E; Zolty R; Efthimiou P
    Int J Rheum Dis; 2014 Mar; 17(3):336-40. PubMed ID: 24581387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Hirano T; Ohguro N; Hohki S; Hagihara K; Shima Y; Narazaki M; Ogata A; Yoshizaki K; Kumanogoh A; Kishimoto T; Tanaka T
    Mod Rheumatol; 2012 Apr; 22(2):298-302. PubMed ID: 21748365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targeting of the interleukin-6 receptor.
    Tanaka T; Narazaki M; Kishimoto T
    Annu Rev Pharmacol Toxicol; 2012; 52():199-219. PubMed ID: 21910626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of blocking IL-6 receptor.
    Mima T; Nishimoto N
    Curr Opin Rheumatol; 2009 May; 21(3):224-30. PubMed ID: 19365268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutic implication of IL-6 blockade.
    Tanaka T; Kishimoto T
    Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody.
    Mihara M; Nishimoto N; Ohsugi Y
    Expert Opin Biol Ther; 2005 May; 5(5):683-90. PubMed ID: 15934843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of refractory intestinal Behçet's disease treated with tocilizumab, a humanised anti-interleukin-6 receptor antibody.
    Chen J; Chen S; He J
    Clin Exp Rheumatol; 2017; 35 Suppl 108(6):116-118. PubMed ID: 28980896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab in refractory adult-onset Still's disease with aseptic meningitis--efficacy of interleukin-6 blockade and review of the literature.
    Sabnis GR; Gokhale YA; Kulkarni UP
    Semin Arthritis Rheum; 2011 Feb; 40(4):365-8. PubMed ID: 20621335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
    Nishimoto N
    Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
    Tanaka T; Narazaki M; Ogata A; Kishimoto T
    Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic uses of anti-interleukin-6 receptor antibody.
    Kang S; Tanaka T; Kishimoto T
    Int Immunol; 2015 Jan; 27(1):21-9. PubMed ID: 25142313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical benefits of anti-human IL-6 receptor antibody therapy].
    Nishimoto N
    Clin Calcium; 2007 Apr; 17(4):562-8. PubMed ID: 17404486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis.
    Yokota S; Kishimoto T
    Expert Rev Clin Immunol; 2010 Sep; 6(5):735-43. PubMed ID: 20828281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab.
    Sumida K; Ubara Y; Hoshino J; Suwabe T; Hiramatsu R; Hasegawa E; Hayami N; Yamanouchi M; Sawa N; Takemoto F; Takaichi K
    Clin Rheumatol; 2010 Oct; 29(10):1191-4. PubMed ID: 20225049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.
    Murakami M; Nishimoto N
    Curr Opin Rheumatol; 2011 May; 23(3):273-7. PubMed ID: 21427577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-6 as a key player in systemic inflammation and joint destruction.
    Fonseca JE; Santos MJ; Canhão H; Choy E
    Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases?
    Febbraio MA; Rose-John S; Pedersen BK
    Clin Pharmacol Ther; 2010 Apr; 87(4):396-8. PubMed ID: 20305672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.